AccessibilityHelp
Kane Biotech logo

Kane Biotech(OTC) KNBIF

Market Cap$3.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-97%
5 Year-86%
1 Year-38%
1 Month+1%
$0.02
+0.00%
+0.00Today
Kane Biotech last closing stock price
MetricPriceDate
Last closeUSD 0.022026-10-23
Kane Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.05%USD 0.022026-10-16
1 month+0.56%USD 0.022026-09-21
3 month-0.55%USD 0.022026-07-23
Year to date-32.33%USD 0.032025-12-10
1 year-37.93%USD 0.032025-10-16
3 year-68.42%USD 0.062023-10-18
5 year-85.52%USD 0.122021-10-22
Since inception-96.96%USD 0.592011-10-12

Kane Biotech Financials at a Glance

Market Cap

$3.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$38.49K

Net Income (TTM)

-CA$2.70M

EPS (TTM)

-$0.01

P/E Ratio

-2.07

Dividend

$0.00

Beta (Volatility)

-0.02 (Low)

Price

$0.02

Volume

60,000

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.02

52-Week Range

$0.01 - $0.03

Estimated Earnings Date

Nov 26, 2026

KNBIF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kane Biotech

Kane Biotech Inc. is a biotechnology firm focused on the research, development, and commercialization of innovative technologies aimed at preventing and eradicating microbial biofilms. The company offers a diverse range of products, including pet dental care solutions and wound treatment options for both animals and humans.

Products and Services
  • Pet dental care solutions under the StrixNB and bluestem brands
  • DispersinB for treating wounds in animals and humans
  • Alosera shampoos and Aledex coatings for medical devices
Growth Outlook
  • Recent product launches are expected to drive market penetration
  • Expansion into new markets could enhance revenue streams
  • Increased focus on R&D may lead to innovative solutions
Financial Highlights
  • Q2 2026 revenue of 8,146 CAD, a decrease from Q1 2026
  • Trailing twelve months (TTM) net income margin of -69.8%
  • Cash and cash equivalents increased to 855,099 CAD in Q2 2026
Kane Biotech Inc. operates in a niche market with significant growth potential, particularly in the pet care and medical device sectors. The company's innovative approach to addressing microbial biofilms positions it well for future advancements. Despite recent financial challenges, including a negative net income margin, the increase in cash reserves indicates a potential for operational stability. The focus on research and development may yield new products that could enhance revenue and market presence. Investors may find Kane Biotech's unique offerings and growth strategies compelling as the company navigates its path forward in the biotechnology industry.
AI Generated • Oct 4, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Robert B. Huizinga, PhD

Website

www.kanebiotech.com

Headquarters

Winnipeg, MB R3T 6G2, CA

KNBIF Financials

Key Financial Metrics (TTM)

Gross Margin

-503.12%

Operating Margin

-8113.83%

Net Income Margin

-6980.20%

Return on Equity

273.53%

Return on Capital

-199.79%

Return on Assets

-121.29%

Earnings Yield

-48.31%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

205.06M

Volume

60.00K

Avg. Volume

132.38K

Financials (TTM)

Gross Profit

-CA$194.73K

Operating Income

-CA$3.14M

EBITDA

-CA$3.07M

Operating Cash Flow

-CA$2.50M

Capital Expenditure

CA$89.61K

Free Cash Flow

-CA$2.41M

Cash & ST Invst.

CA$855.10K

Total Debt

CA$1.96M

Kane Biotech Performance Analysis

Kane Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 120,392-90.6%
20232023-12-31CAD 110,381-8.3%
20242024-12-31CAD 1,518,9321276.1%
20252025-12-31CAD 306,214-79.8%
Kane Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-69.6%
Q42025-12-31-352.8%
Q12026-03-31301.6%
Q22026-06-30-81.2%
Kane Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.02-23.9%
20232023-12-31CAD -0.0318.1%
20242024-12-31CAD -0.02-43.7%
20252025-12-31CAD -0.01-27.3%
Kane Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-71.4%
Q42025-12-3119.4%
Q12026-03-31-34.5%
Q22026-06-30-5.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$8.15K

-70.9%

Gross Profit

-CA$11.61K

+74.5%

Gross Margin

-1.42%

N/A

Market Cap

$3.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$184.55K

N/A

Employees

20

N/A

Net Income

-CA$834.00K

-139.3%

EBITDA

-CA$775.77K

-292.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$855.10K

-47.0%

Total Debt

CA$1.96M

-24.6%

Accounts Receivable

CA$40.41K

-70.9%

Inventory

CA$480.69K

+43.7%

Long Term Debt

CA$660.61K

-68.0%

Short Term Debt

CA$1.30M

+139.7%

Return on Assets

-1.21%

N/A

Return on Invested Capital

9.42%

N/A

Free Cash Flow

-CA$634.59K

+22.9%

Operating Cash Flow

-CA$634.60K

+17.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PMEDFQscreen Ai Inc.
$0.01-11.25%
BVAXFBioVaxys Technology Corp.
$0.09+9.09%
BUDZWEED, Inc.
$0.02+26.67%
BIXTBioxytran, Inc.
$0.02+3.03%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$12.46-17.84%
EWZiShares - iShares Msci Brazil ETF
$33.97-20.25%
ITUBItaú Unibanco
$7.68-20.58%
XPXP
$15.47-49.13%

Questions About KNBIF

What is the current price of Kane Biotech?

Kane Biotech is trading at $0.02 per share.

What is the 52-week range for Kane Biotech?

Over the past 52 weeks, Kane Biotech has traded between $0.01 and $0.03.

How much debt does Kane Biotech have?

As of the most recent reporting period, Kane Biotech reported total debt of CA$1.38M.

How much cash does Kane Biotech have on hand?

Kane Biotech reported CA$602.45K in cash and cash equivalents in its most recent financial results.

What is Kane Biotech’s dividend yield?

Kane Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services